This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6dcg
From Proteopedia
| Line 1: | Line 1: | ||
==Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology== | ==Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology== | ||
| - | <StructureSection load='6dcg' size='340' side='right' caption='[[6dcg]], [[Resolution|resolution]] 1.45Å' scene=''> | + | <StructureSection load='6dcg' size='340' side='right'caption='[[6dcg]], [[Resolution|resolution]] 1.45Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[6dcg]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DCG OCA]. For a <b>guided tour on the structure components</b> use [http:// | + | <table><tr><td colspan='2'>[[6dcg]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DCG OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6DCG FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=G67:(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)-N-(3-{6-[(propan-2-yl)oxy]pyridin-3-yl}-1H-indazol-5-yl)pyrrolidine-3-carboxamide'>G67</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=G67:(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)-N-(3-{6-[(propan-2-yl)oxy]pyridin-3-yl}-1H-indazol-5-yl)pyrrolidine-3-carboxamide'>G67</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase Mitogen-activated protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.24 2.7.11.24] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase Mitogen-activated protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.24 2.7.11.24] </span></td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6dcg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dcg OCA], [http://pdbe.org/6dcg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dcg RCSB], [http://www.ebi.ac.uk/pdbsum/6dcg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dcg ProSAT]</span></td></tr> |
</table> | </table> | ||
== Function == | == Function == | ||
| Line 21: | Line 21: | ||
==See Also== | ==See Also== | ||
| - | *[[Mitogen-activated protein kinase|Mitogen-activated protein kinase]] | + | *[[Mitogen-activated protein kinase 3D structures|Mitogen-activated protein kinase 3D structures]] |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
[[Category: Mitogen-activated protein kinase]] | [[Category: Mitogen-activated protein kinase]] | ||
[[Category: Alhassan, A B]] | [[Category: Alhassan, A B]] | ||
Revision as of 09:04, 11 November 2020
Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
| |||||||||||
Categories: Large Structures | Mitogen-activated protein kinase | Alhassan, A B | Bishop, R | Boga, S B | Buevich, A | Carr, D | Cooper, A | Cox, K | Dayananth, P | Deng, Y | Desai, J | Doll, R | Gao, X | Gudipati, S | Hesk, D | Hruza, A W | Jin, W | Kelly, J | Kirschmeier, P | Liu, G | Long, B | Mei, H | Muppalla, K | Nan, Y | Paliwal, S | Patel, M | Samatar, A A | Sherborne, B | Shih, N | Shipps, G W | Sun, R | Taylor, S A | Tsui, H | Wang, J | Wang, T | Windsor, W T | Xiao, L | Yao, X | Zhang, L | Zhu, H | Zhu, L | Kinase inhibitor | Kinase selectivity | Map kinase | Serine/ threonine-protein kinase | Transferase | Transferase-transferase inhibitor complex
